Compare Stocks: OKUR, AVTE, ARTV, and CAPR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$10.79 -0.8%	$10.64	$2.22 ▼ $14.53	$531.92M	2.18	258,458 shs	325,035 shs
AVTE Aerovate Therapeutics	$19.45 -2.3%	$21.25	$89.95 ▼ $99.05	$563.76M	0.95	53,591 shs	825,597 shs
CAPR Capricor Therapeutics	$8.64 -4.6%	$11.65	$2.96 ▼ $40.37	$526.74M	0.72	11.55 million shs	2.74 million shs
OKUR OnKure Therapeutics	$3.38 -0.6%	$4.02	$2.23 ▼ $5.38	$137.35M	0.23	150,688 shs	80,088 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	-0.83%	-4.60%	-3.83%	+34.88%	+288.13%
AVTE Aerovate Therapeutics	-2.26%	-7.47%	-11.43%	+27.46%	+160.03%
CAPR Capricor Therapeutics	-4.64%	-12.64%	+124.42%	-65.50%	+33.33%
OKUR OnKure Therapeutics	-0.59%	-4.52%	-16.75%	-20.47%	+31.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$10.79 -0.8%	$10.64	$2.22 ▼ $14.53	$531.92M	2.18	258,458 shs	325,035 shs
AVTE Aerovate Therapeutics	$19.45 -2.3%	$21.25	$89.95 ▼ $99.05	$563.76M	0.95	53,591 shs	825,597 shs
CAPR Capricor Therapeutics	$8.64 -4.6%	$11.65	$2.96 ▼ $40.37	$526.74M	0.72	11.55 million shs	2.74 million shs
OKUR OnKure Therapeutics	$3.38 -0.6%	$4.02	$2.23 ▼ $5.38	$137.35M	0.23	150,688 shs	80,088 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	-0.83%	-4.60%	-3.83%	+34.88%	+288.13%
AVTE Aerovate Therapeutics	-2.26%	-7.47%	-11.43%	+27.46%	+160.03%
CAPR Capricor Therapeutics	-4.64%	-12.64%	+124.42%	-65.50%	+33.33%
OKUR OnKure Therapeutics	-0.59%	-4.52%	-16.75%	-20.47%	+31.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	2.83	Moderate Buy	$39.00	261.45% Upside
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
CAPR Capricor Therapeutics	2.18	Hold	$29.15	237.38% Upside
OKUR OnKure Therapeutics	2.25	Hold	$17.50	417.75% Upside

Current Analyst Ratings Breakdown

Latest OKUR, AVTE, ARTV, and CAPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/25/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/14/2026	OKUR OnKure Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$14.00
8/14/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/31/2026	CAPR Capricor Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/30/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$2.00
7/30/2026	CAPR Capricor Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/30/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$3.50
7/30/2026	CAPR Capricor Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/28/2026	OKUR OnKure Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$7.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	$250K	2,110.09	N/A	N/A	$4.48 per share	2.41
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
CAPR Capricor Therapeutics	$22.27M	22.56	N/A	N/A	$5.53 per share	1.56
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$83.86M	-$3.30	N/A	N/A	N/A	N/A	-53.86%	-48.16%	11/11/2026 (Estimated)
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
CAPR Capricor Therapeutics	-$105.04M	-$2.45	N/A	N/A	N/A	N/A	-56.60%	-43.97%	11/9/2026 (Estimated)
OKUR OnKure Therapeutics	-$59.52M	-$3.50	N/A	N/A	N/A	N/A	-49.01%	-45.77%	11/5/2026 (Estimated)

Latest OKUR, AVTE, ARTV, and CAPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/6/2026	Q2 2026	ARTV Artiva Biotherapeutics	-$0.6251	-$0.63	-$0.0049	-$0.63	N/A	N/A
8/4/2026	Q2 2026	OKUR OnKure Therapeutics	-$0.5350	-$0.31	+$0.2250	-$0.31	$0.17 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	24.16	24.16
AVTE Aerovate Therapeutics	N/A	8.78	8.78
CAPR Capricor Therapeutics	N/A	7.35	7.35
OKUR OnKure Therapeutics	N/A	26.75	26.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
AVTE Aerovate Therapeutics	N/A
CAPR Capricor Therapeutics	21.68%
OKUR OnKure Therapeutics	90.98%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	1.80%
AVTE Aerovate Therapeutics	24.90%
CAPR Capricor Therapeutics	9.20%
OKUR OnKure Therapeutics	2.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	48.89 million	48.01 million	N/A
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
CAPR Capricor Therapeutics	101	58.14 million	52.79 million	Optionable
OKUR OnKure Therapeutics	N/A	40.40 million	39.52 million	N/A

OKUR, AVTE, ARTV, and CAPR Headlines

Recent News About These Companies

OnKure Therapeutics (NASDAQ:OKUR) Shares Up 0.6% - What's Next?

September 4, 2026 | americanbankingnews.com

OnKure Therapeutics (NASDAQ:OKUR) Trading 0.6% Higher - Here's Why

September 4, 2026 | marketbeat.com

OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference

August 31, 2026 | globenewswire.com

OnKure Therapeutics Inc. - Ordinary Shares - Class A

August 19, 2026 | money.usnews.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), OnKure Therapeutics (OKUR) and Alnylam Pharma (ALNY)

August 6, 2026 | theglobeandmail.com

OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

August 4, 2026 | globenewswire.com

OnKure Therapeutics Stock Short Interest Report | NASDAQ:OKUR | Benzinga

July 14, 2026 | benzinga.com

Why OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 5.04%

July 10, 2026 | aaii.comA

OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026

July 2, 2026 | globenewswire.com

OnKure Therapeutics, Inc. Class A

June 9, 2026 | edition.cnn.com

OnKure Shareholders Approve Amended 2024 Equity Incentive Plan

June 4, 2026 | tipranks.com

Onkure Therapeutics (OKUR) Stock Forecast & Price Target

May 22, 2026 | investing.com

OnKure Therapeutics (OKUR) Receives a Buy from Oppenheimer

May 8, 2026 | theglobeandmail.com

OnKure Therapeutics war chest nears $200M following spring stock sale

May 6, 2026 | bizwest.comB

OnKure Therapeutics Reports First Quarter 2026 Financial Results

May 5, 2026 | globenewswire.com

OnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60

April 28, 2026 | msn.com

OnKure Therapeutics (OKUR) Gets a Buy from JonesTrading

April 26, 2026 | theglobeandmail.com

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and ...

March 27, 2026 | finance.yahoo.com

OnKure to sell $150M in stock to fund drug development

March 27, 2026 | bizwest.comB

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

March 27, 2026 | globenewswire.com

OnKure reports nearly $60M cash on hand as drug trials continue

March 19, 2026 | bizwest.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR, AVTE, ARTV, and CAPR Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$10.79 -0.09 (-0.83%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$10.84 +0.05 (+0.42%)

As of 09/9/2026 07:59 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Aerovate Therapeutics NASDAQ:AVTE

$19.45 -0.45 (-2.26%)

As of 09/8/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Capricor Therapeutics NASDAQ:CAPR

$8.64 -0.42 (-4.64%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$8.62 -0.03 (-0.29%)

As of 09/9/2026 07:50 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

OnKure Therapeutics NASDAQ:OKUR

$3.38 -0.02 (-0.59%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$3.37 -0.01 (-0.30%)

As of 09/9/2026 04:10 PM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OKUR, AVTE, ARTV, and CAPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OKUR, AVTE, ARTV, and CAPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OKUR, AVTE, ARTV, and CAPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR, AVTE, ARTV, and CAPR Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

Aerovate Therapeutics NASDAQ:AVTE

Capricor Therapeutics NASDAQ:CAPR

OnKure Therapeutics NASDAQ:OKUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OKUR, AVTE, ARTV, and CAPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OKUR, AVTE, ARTV, and CAPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OKUR, AVTE, ARTV, and CAPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR, AVTE, ARTV, and CAPR Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

Aerovate Therapeutics NASDAQ:AVTE

Capricor Therapeutics NASDAQ:CAPR

OnKure Therapeutics NASDAQ:OKUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools